Advancing Alzheimer's Care: Voyager's Tau-Silencing Gene Therapy Breakthrough

Voyager Therapeutics, Inc. announced the presentation of eight oral and poster sessions at the upcoming American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, scheduled for May 2026, in Boston. A significant highlight will be the late-breaking presentation on its investigational tau-silencing gene therapy, VY1706, which targets Alzheimer's disease and will include three-month good laboratory practice (GLP) toxicology data. The company plans to submit an investigational new drug (IND) application for VY1706 in the second quarter of 2026, with aspirations to initiate first-in-human dosing in the latter half of the year. Voyager is diligently assembling a robust preclinical data package that demonstrates a strong pharmacological and safety profile for VY1706 as it prepares for clinical trials. Furthermore, the company is making strides with its intravenous, brain-targeted TRACER capsids, showcasing ongoing innovations aimed at extending applications beyond the central nervous system to include muscular and neuromuscular targeting, while also enhancing patient eligibility through immune evasion strategies.

According to Precedence Research, the Tau Protein Targeting Therapeutics Market was valued at USD 1,100.00 million in 2025 and is projected to grow from USD 1,314.50 million in 2026 to approximately USD 6,534.16 million by 2035, expanding at a CAGR of 19.50% from 2026 to 2035, driven by increasing investment from pharmaceutical companies and research organizations in innovative therapies for advanced neurodegenerative diseases.

Revolutionizing Gene Therapy: Voyager’s RNA-Based Capsid Innovation

• Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of novel AAV capsids to enable gene therapy.
• Voyager used TRACER to develop novel capsids that, after intravenous delivery, cross the blood-brain barrier and transduce diverse CNS regions and cell types. 
• In cross-species preclinical studies, intravenously delivered TRACER-generated capsids produced widespread CNS payload expression at low doses, supporting multiple development candidates for Voyager’s neurologic gene therapy programs.

Voyager Therapeutics: At the Forefront of Neurogenetic Innovation

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company developing genetic medicines for neurological diseases, including Alzheimer’s, Parkinson’s, ALS, and Friedreich’s ataxia. Its programs leverage the TRACER AAV capsid platform to enhance brain delivery. Voyager advances wholly owned and partnered programs with Alexion, Novartis, AstraZeneca, and Neurocrine.

A recent report by Precedence Research highlights that the Tau Protein Targeting Therapeutics is benefiting from increased research related to Alzheimer’s disease.